LS Investment Advisors LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 38.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,499 shares of the company’s stock after selling 13,666 shares during the period. LS Investment Advisors LLC’s holdings in Eli Lilly and were worth $1,839,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Pathstone Family Office LLC raised its stake in Eli Lilly and by 100.0% during the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after purchasing an additional 29 shares during the period. Vantage Financial Partners Ltd. Inc. purchased a new position in shares of Eli Lilly and in the 2nd quarter valued at $494,000. Acrospire Investment Management LLC raised its stake in shares of Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the period. MPS Loria Financial Planners LLC purchased a new position in shares of Eli Lilly and in the 2nd quarter valued at $128,000. Finally, San Francisco Sentry Investment Group CA purchased a new position in shares of Eli Lilly and in the 2nd quarter valued at $129,000. 76.43% of the stock is currently owned by institutional investors.
LLY has been the topic of a number of research reports. Jefferies Group reissued a “buy” rating and issued a $89.00 target price on shares of Eli Lilly and in a research note on Monday, September 11th. BMO Capital Markets reissued an “underperform” rating and issued a $71.00 target price (down previously from $73.00) on shares of Eli Lilly and in a research note on Wednesday, September 6th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and raised their target price for the company from $84.23 to $88.00 in a research note on Tuesday, October 10th. Piper Jaffray Companies reissued an “overweight” rating and issued a $105.00 target price (up previously from $103.00) on shares of Eli Lilly and in a research note on Friday, September 8th. Finally, Berenberg Bank reissued a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a research note on Thursday, October 26th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $90.25.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s revenue was up 9.0% on a year-over-year basis. During the same period last year, the business earned $0.88 EPS. analysts forecast that Eli Lilly and Company will post 4.21 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.44%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s payout ratio is 98.58%.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of the firm’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $85.14, for a total transaction of $16,602,300.00. Following the transaction, the insider now directly owns 123,513,247 shares of the company’s stock, valued at $10,515,917,849.58. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 592,003 shares of company stock valued at $50,246,641. Company insiders own 0.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/04/eli-lilly-and-company-lly-holdings-trimmed-by-ls-investment-advisors-llc.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.